- Daiichi Sankyo's (DSKYF) edoxaban again proves comparable to warfarin in late stage clinicals.
- In a study of patients with A-fib, 1.5% of those given warfarin experienced a stroke versus 1.18% of those given the highest dose of edoxaban and 1.6% of those given the lower dose.
- Bleeding was less common in those given edoxaban.
- There were also fewer deaths among edoxaban patients.
- Despite the data, some say there isn't enough evidence to warrant wholesale adoption: "The absolute risk reduction is small," a professor at McMaster University’s Department of Medicine tells Bloomberg.
- Competitors: PFE and BMY's Eliquis and JNJ's Xarelto.
at CNBC.com (Apr 7, 2014)